Literature DB >> 11107180

MYCN amplification and 17q in neuroblastoma: evidence for structural association.

S O'Neill1, L Ekstrom, M Lastowska, P Roberts, G M Brodeur, U R Kees, M Schwab, N Bown.   

Abstract

MYCN oncogene amplification in neuroblastoma is statistically associated with gain of chromosome segment 17q21-qter. In neuroblastoma cell lines and primary tumors with MYCN amplification in the form of homogeneously staining regions (hsrs), juxtaposition of chromosome 17 material with MYCN sequences has occasionally been reported, raising the possibility of a physical affinity between MYCN and chromosome arm 17q. We used FISH to test for association between chromosome 17 segments and MYCN in eight neuroblastoma cell lines and two neuroblastoma primary tumors known to include hsrs. Evidence of an association was found in the chromosomes of both primary tumors; in one, a MYCN hsr was inserted into a structurally abnormal chromosome 17, in the other, an hsr in 16p was shown to be flanked by 17 material. In cell line NCG, hsrs in 4q and 16p were flanked by 17q material. These observations confirm the juxtaposition of 17q material with MYCN sequences in some neuroblastomas, and imply that there may be a physical or functional relationship between these two features in MYCN amplified neuroblastoma.

Entities:  

Mesh:

Year:  2001        PMID: 11107180

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  7 in total

1.  Chromosome 2 (2p16) abnormalities in Carney complex tumours.

Authors:  L Matyakhina; S Pack; L S Kirschner; E Pak; P Mannan; J Jaikumar; S E Taymans; F Sandrini; J A Carney; C A Stratakis
Journal:  J Med Genet       Date:  2003-04       Impact factor: 6.318

Review 2.  Neuroblastoma tumour genetics: clinical and biological aspects.

Authors:  N Bown
Journal:  J Clin Pathol       Date:  2001-12       Impact factor: 3.411

3.  Catastrophic ATP loss underlies a metabolic combination therapy tailored for MYCN-amplified neuroblastoma.

Authors:  Krista M Dalton; Timothy L Lochmann; Konstantinos V Floros; Marissa L Calbert; Richard Kurupi; Giovanna T Stein; Joseph McClanaghan; Ellen Murchie; Regina K Egan; Patricia Greninger; Mikhail Dozmorov; Sivapriya Ramamoorthy; Madhavi Puchalapalli; Bin Hu; Lisa Shock; Jennifer Koblinski; John Glod; Sosipatros A Boikos; Cyril H Benes; Anthony C Faber
Journal:  Proc Natl Acad Sci U S A       Date:  2021-03-30       Impact factor: 11.205

4.  SMARCE1 promotes neuroblastoma tumorigenesis through assisting MYCN-mediated transcriptional activation.

Authors:  Xiaosong Hu; Ruochen Liu; Jianbing Hou; Wen Peng; Sicheng Wan; Minghao Xu; Yongsen Li; Guanghui Zhang; Xuan Zhai; Ping Liang; Hongjuan Cui
Journal:  Oncogene       Date:  2022-08-17       Impact factor: 8.756

5.  Centrosome clustering and cyclin D1 gene amplification in double minutes are common events in chromosomal unstable bladder tumors.

Authors:  Javier Del Rey; Esther Prat; Immaculada Ponsa; Josep Lloreta; Antoni Gelabert; Ferran Algaba; Jordi Camps; Rosa Miró
Journal:  BMC Cancer       Date:  2010-06-11       Impact factor: 4.430

6.  An ALYREF-MYCN coactivator complex drives neuroblastoma tumorigenesis through effects on USP3 and MYCN stability.

Authors:  Zsuzsanna Nagy; Janith A Seneviratne; Maxwell Kanikevich; William Chang; Chelsea Mayoh; Pooja Venkat; Yanhua Du; Cizhong Jiang; Alice Salib; Jessica Koach; Daniel R Carter; Rituparna Mittra; Tao Liu; Michael W Parker; Belamy B Cheung; Glenn M Marshall
Journal:  Nat Commun       Date:  2021-03-25       Impact factor: 14.919

Review 7.  Targeting Oncogenic Transcriptional Networks in Neuroblastoma: From N-Myc to Epigenetic Drugs.

Authors:  Roberto Ciaccio; Piergiuseppe De Rosa; Sara Aloisi; Marta Viggiano; Leonardo Cimadom; Suleman Khan Zadran; Giovanni Perini; Giorgio Milazzo
Journal:  Int J Mol Sci       Date:  2021-11-28       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.